BerGenBio ASA (BRRGF)
USD 2.5
(0.0%)
USD 2.5
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 41.03 Thousand USD | 46.37% |
| 2022 | 28.03 Thousand USD | -84.75% |
| 2021 | 183.81 Thousand USD | -21.97% |
| 2020 | 235.57 Thousand USD | 253.86% |
| 2019 | 66.57 Thousand USD | 0.0% |
| 2018 | - USD | -100.0% |
| 2017 | 2.48 Million USD | 18.75% |
| 2016 | 2.09 Million USD | 37.89% |
| 2015 | 1.51 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - USD | -100.0% |
| 2024 Q2 | - USD | 0.0% |
| 2023 Q1 | 62.04 Thousand USD | 121.29% |
| 2023 Q2 | - USD | -100.0% |
| 2023 FY | 41.03 Thousand USD | 46.37% |
| 2023 Q3 | 9435.42 USD | 0.0% |
| 2023 Q4 | 41.03 Thousand USD | 334.92% |
| 2022 Q2 | 65.66 Thousand USD | -27.33% |
| 2022 FY | 28.03 Thousand USD | -84.75% |
| 2022 Q4 | 28.03 Thousand USD | 0.0% |
| 2022 Q3 | - USD | -100.0% |
| 2022 Q1 | 90.36 Thousand USD | -50.84% |
| 2021 Q1 | 153.34 Thousand USD | 0.0% |
| 2021 Q4 | 183.81 Thousand USD | 58.4% |
| 2021 Q3 | 116.04 Thousand USD | -19.47% |
| 2021 Q2 | 144.09 Thousand USD | -6.03% |
| 2021 FY | 183.81 Thousand USD | -21.97% |
| 2020 FY | 235.57 Thousand USD | 253.86% |
| 2019 FY | 66.57 Thousand USD | 0.0% |
| 2018 FY | - USD | -100.0% |
| 2017 FY | 2.48 Million USD | 18.75% |
| 2016 FY | 2.09 Million USD | 37.89% |
| 2015 FY | 1.51 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.9% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 99.004% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.851% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.905% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.862% |
| Mesoblast Limited | 118.7 Million USD | 99.965% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 95.672% |
| Genus plc | 233.1 Million USD | 99.982% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 98.6% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 96.946% |
| Marizyme, Inc. | 18.71 Million USD | 99.781% |
| ContraFect Corporation | 2.88 Million USD | 98.576% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 94.528% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | 69.711% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 97.163% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 98.236% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 99.275% |
| MultiCell Technologies, Inc. | 202.58 USD | -20157.182% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.929% |
| EV Biologics, Inc. | 1.49 Million USD | 97.255% |
| Q BioMed Inc. | 4.1 Million USD | 99.002% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.876% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 93.487% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 96.659% |
| Biomind Labs Inc. | 735.54 Thousand USD | 94.421% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.976% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 99.684% |
| Skye Bioscience, Inc. | 4.61 Million USD | 99.111% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 95.379% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | 71.002% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 99.301% |
| IMV Inc. | 28.88 Million USD | 99.858% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -59.559% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 98.183% |
| GB Sciences, Inc. | 1.75 Million USD | 97.667% |
| Alpha Cognition Inc. | 1.22 Million USD | 96.637% |
| HST Global, Inc. | 98.31 Thousand USD | 58.261% |
| CSL Limited | 12.18 Billion USD | 100.0% |
| Halberd Corporation | 150 Thousand USD | 72.642% |
| Enzolytics Inc. | 996.33 Thousand USD | 95.881% |
| Resverlogix Corp. | 6.49 Million USD | 99.368% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | 91.406% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 83.944% |
| argenx SE | 20 Million USD | 99.795% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.91% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 98.485% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -301.34% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.99% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | 79.545% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 98.289% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | 82.103% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.939% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 98.644% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 88.592% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 99.798% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | 72.394% |
| BioStem Technologies, Inc. | 4.71 Million USD | 99.129% |
| ONE Bio Corp. | 19.71 Million USD | 99.792% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 83.597% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 83.501% |
| Agentix Corp. | 50 Thousand USD | 17.926% |
| LadRx Corporation | 33.6 Thousand USD | -22.112% |
| Cell Source, Inc. | 9.25 Million USD | 99.557% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 94.573% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 94.573% |
| NovAccess Global Inc. | 2.19 Million USD | 98.135% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 99.42% |
| Itoco Inc. | 228.37 Thousand USD | 82.031% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | 80.549% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 99.176% |
| Kadimastem Ltd | 891.22 Thousand USD | 95.395% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 89.788% |
| CytoDyn Inc. | 30.07 Million USD | 99.864% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 91.526% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | 88.337% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 99.475% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | 66.5% |
| Rebus Holdings, Inc. | 310 Thousand USD | 86.762% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 99.133% |
| International Stem Cell Corporation | 4.17 Million USD | 99.018% |
| Bioxytran, Inc. | 1.92 Million USD | 97.868% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 34.249% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 98.118% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 99.507% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 99.522% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 97.362% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 84.688% |
| Neutra Corp. | 54.15 Thousand USD | 24.224% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 97.758% |
| PureTech Health plc | 25.51 Million USD | 99.839% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 96.648% |
| IXICO plc | 472.02 Thousand USD | 91.306% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 99.735% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.934% |
| CSL Limited | 12.18 Billion USD | 100.0% |
| Cellectis S.A. | 92.77 Million USD | 99.956% |